Skip to content

Randomised trial, 2004

Does rofecoxib prevent migraines around menstruation?

Yes, rofecoxib significantly reduced how often migraines occurred, cutting them roughly in half. Intensity and duration did not improve.

Early or limited evidence 14 women with menstrually associated migraines

What they did

14 women with migraines around their period were randomly given 25 mg or 50 mg of rofecoxib daily for 10 days, starting 5 days before menstruation. They continued for 2 consecutive menstrual cycles and recorded headaches in a diary.

What they found

Average migraines per cycle dropped from 5.6 to 2.6 (P=.005). Eight women (57%) had at least 50% reduction in migraine frequency. Headache intensity, duration, and functional impairment did not significantly improve. Both doses were well tolerated.

What it means for you

Rofecoxib appears effective at reducing how often menstrual migraines occur but does not make them less painful or shorter. This is a small pilot study, so larger studies are needed. Both doses worked similarly.

14

women studied

5.6 to 2.6

migraines per cycle (before to after)

57%

women with 50% or more reduction

About the study

Original title
Rofecoxib in the prevention of perimenstrual migraine: an open-label pilot trial
Authors
Von Seggern RL, Mannix LK, Adelman JU
Journal
Headache
Year
2004
Study design
Randomised trial
Participants
14
What was tested
Rofecoxib 25 mg or 50 mg daily for 10 days before and during menstruation, for 2 cycles

Topics